Madrigal Pharmaceuticals is developing novel, high-quality small-molecule drugs addressing major unmet needs in cardiovascular and metabolic diseases. The Company is targeting treatment of both niche and prevalent indications, including fatty liver disease and non-alcoholic steatohepatitis (NASH), diabetes, dyslipidemia and cardiovascular disease. Madrigal’s lead drug candidate is MGL-3196, a Phase 2 ready orally administered liver-directed thyroid hormone receptor-ß (THR-ß) agonist. In Madrigal’s 14-day multiple dose Phase 1 study in healthy volunteers with mildly elevated LDL cholesterol, MGL-3196 demonstrated safety and excellent tolerability at all doses tested. In the multiple dose study, MGL-3196 demonstrated proof-of-concept for lipid lowering including dose-dependent, highly significant, up to 30% lowering of LDL cholesterol and non-HDL cholesterol, and a strong trend of up to 60% triglyceride lowering. These results suggest that MGL-3196 has a unique lipid lowering profile as compared with other agents and a potential to significantly reduce cholesterol, triglycerides and liver triglycerides. Elevated cholesterol, triglycerides and fatty liver are an underlying cause of many metabolic and cardiovascular diseases, which, themselves, are associated with increased mortality. In addition, MGL-3196 is a NASH target supported by compelling human biology and genetics. NASH is a serious liver disease found in individuals with fatty liver disease that is associated with hypothyroidism, diabetes, obesity, and dyslipidemia. MGL-3196 Phase 1 human data demonstrate safety and benefit in NASH-related dyslipidemia, and data from MGL-3196 treated NASH animal models support efficacy in NASH at doses relevant to humans.

EVENTS & PRESENTATIONS

Corporate Presentation

September 2016

download

 

CHI 14th Annual Discovery On Target – Targeting Cardio-Metabolic Diseases

Thyroid Hormone Receptor Beta (THR-ß) Agonist for NASH: Correcting a Primary Deficiency in NASH Livers. A presentation by Madrigal Chief Medical Officer and Executive Vice President, R&D, Rebecca Taub, MD.
September 21, 2016 | Boston, MA

See more Events


NEWS

Madrigal Pharmaceuticals and Tarveda Therapeutics Announce Exclusive License Agreement for HSP90 Drug Conjugate Oncology Platform

September 19, 2016
download

Richard S. Levy, MD, Appointed to Madrigal Board of Directors

August 11, 2016
download

See more News